Table 1.
Patient | Pre-oCRH C/P ratio | Post-oCRH stimulation C/P ratio | Tumor location | Treatment outcome | Histopathological confirmation a | ||
---|---|---|---|---|---|---|---|
MRI | BIPSS basal/CRH stimulation | Surgery | |||||
1 | 21.5 | 63.2 | normal | R | R | no relapse | microadenoma |
2 | 9.3 | 23.3 | normal | L | C | no relapse | microadenoma |
3 | 0.8 | 1.1 | heterogenous | lateralization (-) |
C | no relapse | microadenoma |
4 | 1.5 | 1.4 | normal | lateralization (-) |
L | no relapse | microadenoma |
5 | 3.7 | 19.5 | 3mm (L) | L | L | no relapse | microadenoma |
6 | 14.9 | 27.0 | heterogenous | R | R | no relapse | microadenoma |
7 | 8.3 | 22.4 | 4mm (R) | R | R | 2 x surgery RTX bilateral adrenalectomy |
1.microadenoma 2.microadenoma |
8 | 1.3 | 5.6 | normal | R | C | 2 x surgery | 1.microadenoma 2.microadenoma |
9 | 94.5 | 750.2 | normal | R | L | no relapse | corticotropin cell hyperplasia, IHC ACTH (+) |
10 | 43.4 | 115 | heterogenous | R | R | no relapse | pituitary |
11 | 15.8 | 20.3 | heterogenous | R | R | no relapse | microadenoma, IHC ACTH (-) |
12 | 30.7 | 303.4 | normal | L | L | 2 x surgery | 1.microadenoma, IHC ACTH (+) 2.microadenoma |
R, right; L, left; IHC, immunohistochemistry.
IHC staining for ACTH was performed since 2016.